Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May;124(5):337-55.
doi: 10.1111/apm.12514. Epub 2016 Jan 26.

Current status on microRNAs as biomarkers for ovarian cancer

Affiliations
Review

Current status on microRNAs as biomarkers for ovarian cancer

Kira Philipsen Prahm et al. APMIS. 2016 May.

Abstract

Ovarian cancer (OC) is the most lethal gynecological malignancy in the Western world, and has a very poor prognosis, often due to late diagnosis and emergence of chemotherapy resistance. Therefore, there is an essential need for new diagnostic and prognostic markers that can improve and initiate more personalized treatment, eventually improving survival of the patients. MicroRNAs are small, non-coding RNA molecules, that post-transcriptionally regulate gene expression. Several studies have within the last decade shown that microRNAs are deregulated in OC and have potential as diagnostic and prognostic biomarkers for OC. Recently studies have also focused on microRNAs as predictors of chemotherapy responses and their potential as therapeutic targets. However, many of the published studies are difficult to interpret as a whole due to various methods of analysis. Future focus should be aimed at developing a general standardized analytical method, which can limit differences between studies thus allowing easier comparison across them. In addition, validation of studies in independent series that ideally should be histotype-specific is essential to determine the clinical role of microRNAs in different types of OC. In this review we summarize the current knowledge of microRNAs as potential biomarkers for OC, with focus on their clinical relevance.

Keywords: MicroRNA; biomarkers; ovarian cancer.

PubMed Disclaimer

Similar articles

  • Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.
    Mandilaras V, Vernon M, Meryet-Figuière M, Karakasis K, Lambert B, Poulain L, Oza A, Denoyelle C, Lheureux S. Mandilaras V, et al. Expert Opin Biol Ther. 2017 Aug;17(8):927-943. doi: 10.1080/14712598.2017.1340935. Epub 2017 Jun 22. Expert Opin Biol Ther. 2017. PMID: 28641048 Review.
  • Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
    Mahdian-Shakib A, Dorostkar R, Tat M, Hashemzadeh MS, Saidi N. Mahdian-Shakib A, et al. Biomed Pharmacother. 2016 Dec;84:592-600. doi: 10.1016/j.biopha.2016.09.087. Epub 2016 Sep 30. Biomed Pharmacother. 2016. PMID: 27694003 Review.
  • MicroRNAs as prognostic markers in ovarian cancer.
    Llauradó M, Majem B, Altadill T, Lanau L, Castellví J, Sánchez-Iglesias JL, Cabrera S, De la Torre J, Díaz-Feijoo B, Pérez-Benavente A, Colás E, Olivan M, Doll A, Alameda F, Matias-Guiu X, Moreno-Bueno G, Carey MS, Del Campo JM, Gil-Moreno A, Reventós J, Rigau M. Llauradó M, et al. Mol Cell Endocrinol. 2014 Jun 5;390(1-2):73-84. doi: 10.1016/j.mce.2014.03.006. Epub 2014 Apr 18. Mol Cell Endocrinol. 2014. PMID: 24747602 Review.
  • microRNA and Ovarian Cancer.
    Langhe R. Langhe R. Adv Exp Med Biol. 2015;889:119-51. doi: 10.1007/978-3-319-23730-5_8. Adv Exp Med Biol. 2015. PMID: 26659000 Review.
  • MicroRNAs in Ovarian Cancer.
    Katz B, Tropé CG, Reich R, Davidson B. Katz B, et al. Hum Pathol. 2015 Sep;46(9):1245-56. doi: 10.1016/j.humpath.2015.06.013. Epub 2015 Jun 30. Hum Pathol. 2015. PMID: 26216350 Review.

Cited by

LinkOut - more resources